Hunting for the last remaining tumour cell

October 29, 2012
Cells that are freed from the primary tumour circulate in the blood, when they surivive they can form metastases, or stay dormant for a while.

The 7.5 millilitres of blood contained in a standard sample tube is not nearly enough to detect circulating tumour cells (CTCs) in the blood of patients with metastatic breast cancer, prostate cancer, or colorectal cancer with a high enough degree of reliability. These CTCs are the cause of metastases in cancer patients. If they can be effectively characterized, it is possible to arrive at a prognosis and to determine the most effective course of treatment. However, the only way to detect "that one particular cell" is to subject the patient's entire blood volume to a kind of dialysis. This was the conclusion reached by Dr Frank Coumans in an article published in the journal Clinical Cancer Research. Dr Coumans works at the University of Twente's MIRA Institute for Biomedical Technology and Technical Medicine. He was recently awarded a PhD (with distinction) on this topic.

The standard test for circulating (CTCs) involves a 7.5 millilitre blood sample and the use of to separate CTCs from the other components of the blood. However, Dr Coumans found that this method failed to detect any CTCs in nearly half of those patients who are known to have metastases. Accordingly, for these patients, this method is an insufficiently reliable indicator of metastases. Furthermore, if no CTCs can be isolated, it will not be possible to develop treatment plans that are tailored to individual patients.

Difficult to identify

Schematic drawing of the CTC Trap setup, analysing the entire blood volume of the patient.

There are several reasons for this. It is no easy matter to pick out CTCs, as they resemble many of the cells that are normally found in the blood. For this reason, the test focuses on specific indicators. One of these is the epithelial (EpCAM), which "sticks cells together" in organs, but which is not normally found in blood cells. Other such indicators are cytokeratin and CD45, a protein found in all . Any white blood cells that unexpectedly contain traces of EpCAM and cytokeratin but very little CD45 could mistakenly be counted as circulating tumour cells. Errors can also creep into the count during the enrichment of CTCs from blood using magnetic particles. For instance, the magnetic field used might be too weak to capture the CTCs. Finally, if the concentration of CTCs is sufficiently low, there is only a small chance that any of these cells will be present in the blood sample. The latter turned out to be the case. Taking two blood samples rather than one has no effect whatsoever. The concentration of CTCs is logarithmic, so doubling the sample size does not double the chances of finding one of these cells.

Large volume

Frank Coumans carried out his PhD research in Prof. Leon Terstappen's Medical Cell Biophysics group. Research previously carried out by this group showed that gains can still be made, for example, by using an improved CellSearch analyser, with better illumination. However, according to Dr Coumans, the only way to achieve a 99 percent chance of detecting a CTC is to sample a of five litres. This approach would involve the use of additional technology. This works best with fresh blood, so a type of dialysis or apheresis is needed that can separate specific components from the blood and return "the rest" to the patient. This is known as the CTCtrap or CTC TheRapeutic APheresis.

Dr Coumans' research is part of a major European research programme (http://www.utwente.nl/tnw/ctctrap/). He expects this programme to deliver a technique capable of entering the clinical phase. often dramatically worsen the prognoses of . It is therefore vital to improve the chances of a CTC "hit" and to better understand the mechanisms involved.

The article entitled "Challenges in the Enumeration and Phenotyping of CTC" by Frank Coumans, Sjoerd Ligthart, Jonathan Uhr and Leon Terstappen, was published in , the journal of the American Association for Cancer Research (ACCR).

Explore further: Individual therapy for all cancer patients

Related Stories

Individual therapy for all cancer patients

June 26, 2012
In cancer patients, mortality is generally associated with metastases. The ability to detect “circulating tumor cells” (CTCs) in blood is crucial if we are to uncover the mechanisms that lead to metastases. In the ...

Cancer cells in blood predict chances of survival and can help target breast cancer treatment

March 22, 2012
Detecting the presence of circulating tumour cells (CTCs) in the blood of women with early breast cancer after surgery but before the start of chemotherapy can provide useful information about their chances of surviving the ...

Blood test could lead to improved diagnosis and treatment of breast cancer

June 5, 2012
Scientists have discovered that a simple blood test could lead to better diagnosis and treatment for early-stage breast cancer patients, according to an Article published Online First in The Lancet Oncology.

Researchers identify potential treatment target for metastatic pancreatic cancer using CTC chip technology

July 30, 2012
(Medical Xpress) -- Researchers with the Stand Up To Cancer CTC Chip Dream Team have identified a potential treatment target in metastatic pancreatic cancer through a detailed analysis of genes expressed in circulating tumor ...

Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer

December 9, 2011
The presence of circulating tumor cells in the blood appears to have no relationship to survival in women who have just been diagnosed with inflammatory breast cancer, according to new research from Fox Chase Cancer Center. ...

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.